Ask AI
ProCE Banner Activity

Experts Discuss Optimal Treatment for ALK-Positive Advanced NSCLC

Clinical Thought

In this commentary derived from a recent webinar, expert faculty discuss ALK testing and treatment options for patients with ALK-positive advanced NSCLC, including therapeutic sequencing and recognizing and mitigating key adverse events with ALK-targeted therapy.

Released: July 28, 2025

Expiration: January 27, 2026

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Pfizer Inc.

Pfizer Inc.

Disclosure

Primary Author

Todd M. Bauer, MD: consultant/advisor/speaker: Bayer, FMI, Pfizer, Tempus.

Christine Bestvina, MD: consultant/advisor/speaker: AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, EMD Serono, Genentech, Gilead, Guardant, Johnson & Johnson, Mirati, Novocure, Pfizer, Sanofi, Tempus, Turning Point Therapeutics; researcher (paid to institution): AstraZeneca, Bristol Myers Squibb; other financial or material support: AstraZeneca, Bristol Myers Squibb, Guardant, Johnson & Johnson.